Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma

To determine whether the addition of pp65-LAMP mRNA DC vaccine plus GM-CSF and Td to dose-intensified TMZ treatment is worthy of investigation in a large phase III study based on impact on overall survival. Secondary Objectives Evaluate the impact of CMV pp65-LAMP RNA-pulsed DC vaccines on progression-free survival in patients with newly-diagnosed GBM. Determine the immunologic effects of vaccination with pp65 RNA fusion constructs incorporating full-length LAMP vs short LAMP sequences.

July 03, 2017